Biblio
“Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals.”, J Alzheimers Dis, vol. 100, no. 1, pp. 193-205, 2024.
, “Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1267-1282, 2022.
, “A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD Project.”, J Alzheimers Dis, vol. 83, no. 3, pp. 1149-1159, 2021.
, “Multicenter Resting State Functional Connectivity in Prodromal and Dementia Stages of Alzheimer's Disease.”, J Alzheimers Dis, vol. 64, no. 3, pp. 801-813, 2018.
, “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
, “Face-Name Associative Recognition Deficits in Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 56, no. 3, pp. 1185-1196, 2017.
, “In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 465-471, 2017.
, “Differential Risk of Incident Alzheimer's Disease Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline.”, J Alzheimers Dis, vol. 54, no. 3, pp. 1135-1146, 2016.
, “The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 49, no. 2, pp. 547-60, 2016.
, “Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.”, PLoS One, vol. 5, no. 11, p. e13950, 2010.
,